Research and Development

Corcept Therapeutics has announced results from its phase 2 DAZALS study investigating dazucorilant in patients with amyotrophic lateral sclerosis (ALS), …

Elgan Pharma, specialising in neonatology, and Italy-based biopharma, Chiesi Farmaceutici, have announced the dosing of the first participating infants in …

Researchers at Chiba University, Japan, alongside Niagen Bioscience, have reported successful results from the world’s first trial of nicotinamide riboside …

Osivax has announced the completion of patient visits in its phase 2a trial evaluating a booster dose of OVX836, a …

BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise BNT327, BioNTech’s bispecific antibody, to …

Roche has received approval from the European Commission for a new tablet formulation of Evrysdi (risdiplam), marking the first and …

An international study has found an increased risk of Guillain-Barré syndrome (GBS) following SARS-CoV-2 infection and after vaccination with adenoviral …

Dr Werner Engelbrecht at Veeva Systems discusses how compliance can be turned into a competitive advantage with connected platforms and …

Japan-based biopharma, NIPRO, has launched LiniXia, a new reverse osmosis (RO) water treatment system for haemodialysis. It was unveiled at …

Evosep has launched Evosep Eno, a new high-throughput separation platform designed to support next-generation workflows in liquid chromatography-mass spectrometry (LC-MS)-based …

LEO Pharma has initiated a phase 2a trial investigating delgocitinib cream in adults with mild-to-severe palmoplantar pustulosis (PPP). The DELTA …

Sanofi and Blueprint Medicines Corporation, a US biopharma, have entered into an agreement under which Sanofi will acquire Blueprint. This …

For people living with aggressive blood cancers, CAR T-cell therapy offers hope for a longer, healthier life, and for some, …

UK-based biotech Gene Weaver has received $515,000 from the Bill and Melinda Gates Foundation to advance its programmable gene insertion technology …

Ochre Bio has appointed Elaine Sullivan as senior independent non-executive director. She joins the Oxford-based RNA therapeutics company with a …